Related Experiment Video
Updated: Apr 28, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Rapid molecular genetic diagnosis of hypertrophic cardiomyopathy by semiconductor sequencing
Zongzhe Li, Jin Huang, Jinzhao Zhao
1Departments of Internal Medicine and Gene Therapy Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave, Wuhan 430030, China. david37212@hotmail.com.
Insights
A new genetic testing method significantly speeds up the diagnosis of Hypertrophic cardiomyopathy (HCM). This rapid assay identifies genetic variants from blood samples in a single day, improving patient management for this common cardiovascular disease.
Area of Science:
- Cardiovascular Genetics
- Molecular Diagnostics
Background:
- Hypertrophic cardiomyopathy (HCM) is a common polygenetic cardiovascular disease.
- Understanding the complex genetic basis of HCM is crucial for effective management.
Purpose of the Study:
- To develop and validate a rapid genetic diagnostic assay for Hypertrophic cardiomyopathy.
- To facilitate timely genetic diagnosis of HCM in clinical settings.
Main Methods:
- Development of a custom Ion amplicon-resequencing assay targeting 30 common HCM genes.
- Validation of the assay using 120 unrelated HCM patients with minimal genomic DNA input (20 ng).
- Single-day workflow from blood sample to variant detection.
Main Results:
- The assay achieved high performance metrics: 595,628 mapped reads/sample, 95.51% on-target reads, 490-fold coverage depth, and 93.24% uniformity.
- Pathogenic variants were identified in 87% (104/120) of HCM patients.
- Sanger sequencing validation confirmed 100% sensitivity and a 5% false-positive rate for the panel.
Conclusions:
- The Ion amplicon resequencing assay offers a rapid, comprehensive, cost-effective, and reliable method for HCM genetic diagnosis.
- This assay enables genetic diagnosis from routinely obtained samples within a single day.
Background:
Rapidly determining the complex genetic basis of Hypertrophic cardiomyopathy (HCM) is vital to better understanding and optimally managing this common polygenetic cardiovascular disease.
Methods:
A rapid custom Ion-amplicon-resequencing assay, covering 30 commonly affected genes of HCM, was developed and validated in 120 unrelated patients with HCM to facilitate genetic diagnosis of this disease. With this HCM-specific panel and only 20 ng of input genomic DNA, physicians can, for the first time, go from blood samples to variants within a single day.
Results:
On average, this approach gained 595628 mapped reads per sample, 95.51% reads on target (64.06 kb), 490-fold base coverage depth and 93.24% uniformity of base coverage in CDS regions of the 30 HCM genes. After validation, we detected underlying pathogenic variants in 87% (104 of 120) samples. Tested seven randomly selected HCM genes in eight samples by Sanger sequencing, the sensitivity and false-positive-rate of this HCM panel was 100% and 5%, respectively.
Conclusions:
This Ion amplicon HCM resequencing assay provides a currently most rapid, comprehensive, cost-effective and reliable measure for genetic diagnosis of HCM in routinely obtained samples.
